Lundeen Katherine A, Sun Binggang, Karlsson Lars, Fourie Anne M
Alza/Johnson & Johnson Pharmaceutical Research and Development, San Diego, CA 92121, USA.
J Immunol. 2006 Sep 1;177(5):3439-47. doi: 10.4049/jimmunol.177.5.3439.
Leukotriene B4 (LTB4) is a potent activator and chemoattractant for leukocytes and is implicated in several inflammatory diseases. The actions of LTB4 are mediated by two cell surface receptors, BLT1, which is predominantly expressed in peripheral blood leukocytes, and BLT2, which is expressed more ubiquitously. Recently, BLT1 expression and LTB4-dependent chemotaxis have been reported in immature mast cells (MCs). We now show the first evidence for BLT2 mRNA expression, in addition to BLT1, in murine bone marrow-derived MCs (mBMMCs) and in a human MC line (HMC-1). Protein expression of BLT1 was confirmed by mAb staining in HMC-1 cells and shown to be predominantly intracellular. Both HMC-1 cells and mBMMCs migrated to LTB4 in a dose-dependent manner in chemotaxis assays. Migration to LTB4 could be inhibited by either a BLT1- or BLT2-selective antagonist. Significant dose-dependent migration of mBMMCs also was observed to 12-(S)-hydroxyeicosotetraenoic acid, a BLT2-selective agonist, demonstrating functional BLT2 activity in these cells. Stimulation of mBMMCs with LTB4 induced transient, dose-dependent, ERK phosphorylation and changes in Akt phosphorylation. Dose-dependent ERK phosphorylation also was observed in response to 12-(S)-hydroxyeicosotetraenoic acid, indicating signaling downstream of BLT2. Pretreatment of mBMMCs with stem cell factor significantly down-regulated expression of BLT1 and BLT2 mRNA and inhibited their migration to LTB4. This study demonstrates expression of functional LTB4 receptors, both BLT1 and BLT2, in murine and human MCs and a regulatory role for stem cell factor in their expression. These receptors may mediate recruitment and accumulation of MCs in response to LTB4 production in areas of inflammation.
白三烯B4(LTB4)是一种对白细胞具有强大激活作用和趋化作用的物质,与多种炎症性疾病有关。LTB4的作用由两种细胞表面受体介导,即主要在外周血白细胞中表达的BLT1和表达更为广泛的BLT2。最近,有报道称未成熟肥大细胞(MCs)中存在BLT1表达和LTB4依赖性趋化作用。我们现在首次证明,除了BLT1之外,在小鼠骨髓来源的MCs(mBMMCs)和人MC系(HMC-1)中也存在BLT2 mRNA表达。通过单克隆抗体染色在HMC-1细胞中证实了BLT1的蛋白表达,且显示其主要位于细胞内。在趋化实验中,HMC-1细胞和mBMMCs均以剂量依赖性方式向LTB4迁移。向LTB4的迁移可被BLT1或BLT2选择性拮抗剂抑制。还观察到mBMMCs对BLT2选择性激动剂12-(S)-羟基二十碳四烯酸有显著的剂量依赖性迁移,证明这些细胞中存在功能性BLT2活性。用LTB4刺激mBMMCs可诱导瞬时、剂量依赖性的ERK磷酸化以及Akt磷酸化的变化。对12-(S)-羟基二十碳四烯酸的反应也观察到剂量依赖性的ERK磷酸化,表明BLT2下游的信号传导。用干细胞因子预处理mBMMCs可显著下调BLT1和BLT2 mRNA的表达,并抑制它们向LTB4的迁移。本研究证明了功能性LTB4受体BLT1和BLT2在小鼠和人MCs中的表达,以及干细胞因子在其表达中的调节作用。这些受体可能介导MCs在炎症区域响应LTB4产生时的募集和聚集。